Sales & Marketing Is pure play pharma's new pharmakon? The shift in commercial teams has been happening for some time. This is not new news. I have felt it many times over, like many of us who have worked in the industry for years.
Digital The cliff was never the crisis: Pharma’s strategy problem The patent cliff isn't the problem. It's the symptom.
Event Partner Content WOMA 2026: Steering the Future of Pharma Strategy The WOMA Forum is not merely a conference. It's a convergence point for decision-makers
Sales & Marketing Execution drift: Why pharmaceutical go-to-market falls short... Execution drift occurs when strategy, targeting, metrics, incentives, and behaviour gradually stop reinforcing one another.
R&D Rare disease at an inflection point: Why the next wave will ... As rare disease becomes more competitive, information parity is disappearing.
News MSD splits pharma business, hiving off oncology MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.
News TransThera's resistant biliary cancer drug cleared in China TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.